ERBB2 and colorectal carcinoma: A more profound molecular characterization established upfront [109] or at the time of disease progression [110], a better understanding of the optimal treatment sequences [111], the possibility to drive targeted treatments with easily repeatable tests [112], and the development of novel, potent inhibitors [113], will shape the near future and lead forthcoming clinical improvements in HER-2 positive CRC tumors.